Pembrolizumab in HER2-Positive Gastric Cancer

The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-10, Vol.391 (14), p.1360-1362
Hauptverfasser:	Janjigian, Yelena Y., Kawazoe, Akihito, Bai, Yuxian, Xu, Jianming, Lonardi, Sara, Metges, Jean Phillipe, Yañez, Patricio, Wyrwicz, Lucjan S., Shen, Lin, Ostapenko, Yuriy, Bilici, Mehmet, Chung, Hyun Cheol, Shitara, Kohei, Qin, Shukui, Van Cutsem, Eric, Tabernero, Josep, Luo, Suxia, Mahave, Mauricio, Tang, Yong, Lowery, Maeve, Monteiro, Maria M.F., Xu, Linzhi, Shih, Chie-Schin, Sharan, Kanu P., Bhagia, Pooja, Rha, Sun Young
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols Cancer therapies Chemotherapy Double-Blind Method ErbB-2 protein Esophagogastric Junction - pathology Female Gastric cancer Gastroenterology Gastrointestinal Tract Cancer Hematology Humans Ligands Male Metastasis Middle Aged Oncology Pembrolizumab Progression-Free Survival Receptor, ErbB-2 - analysis Receptor, ErbB-2 - metabolism Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology Trastuzumab Trastuzumab - therapeutic use Treatments in Oncology
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMc2408121